ABOUT US
Alkannoli LDA is a new entrant in the European medical cannabis industry and is located in Portugal.
The company will produce high-quality extracts from medical cannabis for medical applications.
Alkannoli’s vision is to make products available for the medical sector that can effectively alleviate human illness, disease, and suffering.
MISSION
To establish a cutting-edge production facility in Portugal dedicated to producing high-quality extracts and active pharmaceutical ingredients (APIs) from medical cannabis, adhering to the latest environmental standards and optimal working conditions.
PROCESS
Our approach emphasizes quality through selective genetics and advanced, technology-driven cultivation methods, utilizing highly efficient and environmentally sustainable extraction equipment and systems.
GOAL
Our objective is to provide the medical sector with superior active ingredients derived from medical cannabis, aimed at enhancing therapeutic applications and patient outcomes.
THE
ALKANNOLI
SET-UP
A Cultivation and GMP manufacturing facility of approximately 2,000 m2 is being developed to cultivate and produce medical cannabis products including cannabis oral solutions, full spectrum extracts, cannabis oils and isolates.
Our manufacturing facility will be used both to develop Kannoli Pharma’s specific genetics, grow small scale commercial batches of medical cannabis Flower and do offtake agreements with other licensed national and international medical cannabis cultivators.
Timeline
Start up
– Company established
– Company strategy developed
– Contracts with potential suppliers and off takers established
Site One -selection and contract negotiated
License Applications
– Application for Medical Cannabis License
– Application for cultivation, import and export,
manufacturing and distribution to INFARMED I.P.
Site One Approvals & Design
– Pre-license approval by INFARMED I.P.
– Engineering Detail Design complete
GACP/EU-GMP Pre-License approval
– Achieved
Award of Portugal PT2020
– Achieved
Construction
– GDP Third Party License approved
Site One relinquished
New Site Acquired – Site Two
– PT 2020 award returned
– PT2030 application for Site Two
Site Two Preparation:
– All geological studies concluded
– EPC design complete
– Extraction technology analysis, design and contract complete
– Municipality license in process
Site Two licensing
– EU-GMP Pre-license approval by INFARMED I.P.
Our Team
Prof. Fred Harms is a health care researcher, who studied biochemistry and medicine from 1986 to 1996 at the University of Witten/Herdecke , the University of Münster, the MD Anderson Cancer Center, Houston, Texas, USA and the University of Bangkok, graduating with an MD/PhD in tumor immunology/ oncology.
He is also a member of reputable science associations and academy’s such as New York Academy of Sciences and is also working as a board member of International Prevention Organization (IPO Brussels) since 2006.
Prof. Fred Harms was granted number of scholarships in his research area and was awarded by letter of Honor from the European Commission in Brussels, together with Dorothee Gänshirt in 2010.
Now he has joined our Alkannoli team as the Chief Medical Officer and we are looking forward to bringing high quality products to our costumers through advanced development of medical cannabis.
Sales channel & companies strategy specialist for over 15 years, he has served as Managing Director and CEO for several highly regulated aviation supplier companies in the field of electronics and avionics, execution of several asset deals and M&A transactions. On the investment side he has been active in the field of renewable energy mainly in photovoltaic off-grid systems in India and Pakistan. He currently helps SME companies within EU to define their strategy and to pave the way for their growth. He is acting as Member of the Advisory board for Kannoli Pharma.
Pharmacist since 1989 and Qualified Person (QP) since 2001. Experienced in all dosage forms (i.e., sterile/ nonsterile, small and biological molecules, IMPs/Commercial Products, Human/Veterinary), from R&D to Production, Quality Control, Quality Assurance, batch certification and batch release.
Worked 20 years at Laboratorio Medinfar successively as Head of R&D, Head of Quality Control, Qualified Person and SME of Intellectual Property and Pharmaceutical Industry. Also worked as a Deputy-CEO of Cytothera and as a Member of the Board of Directors and QP of Genibet Biopharmaceuticals, two companies of Medinfar Group.
Senior manager with over 30 years of global experience in business management and development. International experience in sectors such as automotive, machinery, power supply, fleets and project management. General management roles across Europe, West and East Africa, Middle East and Central Asia on MNC’s, SME’s and a private equity.
Christian Geyr is an entrepreneur, gifted photographer, and creative mastermind with a special talent for brand building. He is the co-founder of Noodles Noodles & Noodles Corp., a reference brand in the field of industrial vintage design furniture. Additionally, Christian has significantly influenced the fashion industry as the co-founder of the Bread & Butter fashion trade show, which evolved into Europe's most relevant B2B event in the sector. He has been recognized by GQ as one of Germany's 40 most influential individuals and also co-founded the Parawdiso Restaurant in Ibiza. He is responsible for the creative communication and marketing at Alkannoli LDA.